Company Overview and News

25
E&P 'Bottom Of The Barrel' Club #18-5: Ex-Chapter 11 Company Stats For The First Half Of 2018

2018-09-17 seekingalpha
They're baaack! Actually, some of them have been back for a while, but I have not felt compelled to write about them until now. "They" are, of course, former members of my Bottom of the Barrel Club who declared bankruptcy during the past 2-3 years. The companies in this article are now trading publicly again (with 1 or 2 exceptions). I may refer to them as the "X-11 Club" occasionally.
ECR CHPE UPL GDPMQ LNGG SDRPQ DVN PVA GDAOQ VNR CHAP VNRBP GDRRQ LINEQ TALO GDPM BRMR PVAYQ VNRR HKRCP SBOW SD GDUEQ SDOCQ GDANQ GDP RVRA PVAC SGY HK MPO VNRAP TTEN MPOYQ VNRCP UPLMQ BRY GDPAN SDRXP LINE SDRXQ GDPAQ

12
The Zacks Analyst Blog Highlights: Oasis Midstream, TC PipeLines, Phillips, Chaparral and Northern Oil

2018-09-13 zacks - 1
Chicago, IL –September 13, 2018 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Oasis Midstream Partners LP (OMP - Free Report) , TC PipeLines, LP (TCP - Free Report) , Phillips 66 (PSX - Free Report) , Chaparral Energy, Inc.
OMP CHPE TCP VTNR NOG SUMR PSX CHAP ICE HBIO

8
Hurricane Florence, Iran Fears Boost Oil Prices: 5 Picks

2018-09-12 zacks
The U.S. East Coast, particularly the Carolinas, is bracing itself for what could be the worst hurricane in nearly three decades. Hurricane Florence, a Category 4 storm, is likely to make landfall by early Friday. With smaller storms like Tropical Storm Isaac likely to follow in its wake, fuel demand is experiencing an increase. These storms could also disrupt production and refining activities significantly.
OMP CHPE TCP NOG PSX CHAP

 
Chaparral Energy to Present at Barclay’s CEO Energy-Power Conference

2018-08-29 globenewswire
OKLAHOMA CITY, Aug. 29, 2018 (GLOBE NEWSWIRE) -- Chaparral Energy, Inc. (NYSE: CHAP) today announced the company will present at Barclay’s CEO Energy-Power Conference in New York City on Thursday, September 6 at 9:45 a.m. Eastern Standard Time. A webcast of the company’s presentation will be available at chaparralenergy.com/investors. Chaparral will also hold one-on-one meetings throughout the day.
CHPE CHAP

 
Chaparral Energy to Present at Seaport Global Energy and Industrial Conference

2018-08-23 globenewswire
OKLAHOMA CITY, Aug. 23, 2018 (GLOBE NEWSWIRE) -- Chaparral Energy, Inc. (NYSE: CHAP) today announced the company will be attending the Seaport Global Energy and Industrials Conference in Chicago on Wednesday, August 29, where it will hold one-on-one meetings throughout the day.
CHPE CHAP

 
Chaparral Energy Inc 2018 Q2 - Results - Earnings Call Slides

2018-08-14 seekingalpha
The following slide deck was published by Chaparral Energy Inc in conjunction with their 2018 Q2 earnings call.
CHPE CHAP

 
CHPE / Chaparral Energy Inc FORM 8-K (Current Report)

2018-08-14 sec.gov
Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 CHPE

 
Chaparral Energy Announces Second Quarter 2018 Financial and Operational Results

2018-08-14 globenewswire
OKLAHOMA CITY, Aug. 14, 2018 (GLOBE NEWSWIRE) -- Chaparral Energy, Inc. (NYSE: CHAP) today announced its second quarter 2018 financial and operational results with the filing of its form 10-Q. The company will hold its quarterly financial and operating results conference call this morning, August 14, at 9 a.m. Central.
CHPE CHAP

 
CHPE / Chaparral Energy Inc 10-Q (Quarterly Report)

2018-08-14 sec.gov
chap-10q_20180630.htm
CHPE

18
Gastar Exploration: A Sober View

2018-08-08 seekingalpha - 8
Ares Management filed Schedule 13D/A, attempting to force a sale of Gastar Exploration to recover the debt owed to it and its equity investment.
CHPE GST-A CTLR GST-B GST NFX ARES AMR CHAP CLR

 
Chaparral Energy to Present at EnerCom Oil and Gas Conference

2018-08-08 globenewswire
OKLAHOMA CITY, Aug. 08, 2018 (GLOBE NEWSWIRE) -- Chaparral Energy, Inc. (NYSE:CHAP) today announced the company will present at EnerCom’s Oil and Gas Conference in Denver on Monday, August 20. The company will also hold one-on-one meetings throughout the day Monday and Tuesday, August 20 and 21.
CHPE CHAP

47
Gastar: You Had My Curiosity, But Now You Have My Attention

2018-08-06 seekingalpha - 5
Gastar Exploration has moved quickly from being an undervalued promising E&P play into a kind of binary option bet.
CHPE GST-A LNGG CHKVP GST-B DVN GST CHKDH CHKVZ CHKDG CHKDJ CHKDP AMR CHAP LINEQ CKRGZ NBL CTLR ARES NFX CHKWZ CHK CHK.WI MRO CLR LINE

34
Gestar: You Had My Curiosity, But Now You Have My Attention

2018-08-06 seekingalpha - 1
Gestar exploration has moved quickly from being an undervalued promising E&P play into a kind of binary option bet.
CHPE LNGG CHKVP DVN CHKDH CHKVZ CHKDG CHKDJ CHKDP AMR CHAP LINEQ CKRGZ NBL CTLR ARES NFX CHKWZ CHK CHK.WI MRO CLR LINE

 
Chaparral Energy Schedules Second Quarter 2018 Earnings Release Date and Conference Call

2018-07-31 globenewswire
OKLAHOMA CITY, July 31, 2018 (GLOBE NEWSWIRE) -- Chaparral Energy, Inc. (NYSE: CHAP) today announced it will issue its second quarter 2018 financial and operational results with the filing of its 10-Q report on Tuesday, August 14. The company will also host a conference call to discuss its results that morning at 9 a.m. Central.
CHPE CHAP

 
Chaparral Energy Begins Trading on the New York Stock Exchange Under New Ticker Symbol “CHAP”

2018-07-25 globenewswire
OKLAHOMA CITY, July 25, 2018 (GLOBE NEWSWIRE) -- Chaparral Energy, Inc. (NYSE:CHAP) announced the company’s Class A common stock began trading yesterday, July 24, on the New York Stock Exchange (NYSE) under the new symbol “CHAP.” Upon commencement of trading on the NYSE, the company’s Class A common stock ceased trading on the OTCQB market.
CHPE CHAP DTK

Related Articles

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

EKSO: Ekso Bionics Holdings Analysis and Research Report

2018-09-18 - Asif

Overview The company design, develop and sell exoskeleton technology to augment human strength, endurance and mobility. The company's exoskeleton technology serves multiple markets and can be used both by able-bodied users as well as by persons with physical disabilities. Ekso Bionics has sold, rented or leased devices that (a) enable individuals with neurological conditions affecting gait (stroke and spinal cord injury) to rehabilitate and to walk again and (b) allow industrial workers to perform heavy duty work for extended periods. Today, its medical exoskeleton, Ekso GT, is used as a rehabilitation tool to allow physicians and therapists to rehabilitate patients who have suffered a stroke or spinal cord injury. With its unique features designed specifically for hospitals and its proprietary SmartAssist software, Ekso GT allows for the early mobilization of patients, with high step count and high dosage treatments. The intent is to allow the patient’s central nervous syst...

AGRX: Agile Therapeutics Analysis and Research Report

2018-09-18 - Asif

Overview Agile Therapeutics is a forward-thinking women’s healthcare company dedicated to fulfilling the unmet health needs of today’s women. Twirla® and its other current potential product candidates are designed to provide women with contraceptive options that offer greater convenience and facilitate compliance. The company's lead product candidate, Twirla, also known as AG200-15, is a once-weekly prescription contraceptive patch that is at the end of Phase 3 clinical development. Since its inception in 1997, Agile Therapeutics has devoted substantial resources to developing Twirla, building its intellectual property portfolio, business planning, raising capital and providing general and administrative support for these operations. The company incurred research and development expenses of $14.4 million, $20.9 million and $25.6 million during the years ended December 31, 2017, 2016 and 2015, respectively. The company incurred research and development expenses of $2.4 milli...

Silicon Investor Message Boards

This table lists all message boards related to CHPE / Chaparral Energy Inc on message board site Silicon Investor.

Blue Chip Computerware (BCHPE) Blue Chip Computerware (BCHPE) Blue Chip Computerware (BCHPE)